Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | CFO and EVP Corp. Development | September 22, 2017 | September 26, 2017 |
| DELCATH SYSTEMS, INC.DCTH · Entity 5387 | Director | May 13, 2026 | May 14, 2026 |
| SPECTRUM PHARMACEUTICALS INCSPPI · Entity 111009 | Director | June 18, 2020 | June 19, 2020 |
| Scilex Holding CoSCLX · Entity 7345 | See Remarks | January 17, 2023 | January 17, 2023 |
| Sorrento Therapeutics, Inc.SRNE · Entity 109201 | EVP & Chief Financial Officer | May 18, 2022 | May 20, 2022 |
| Transcode Therapeutics, Inc.RNAZ · Entity 8499 | Director | October 06, 2025 | December 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date September 22, 2017 · Filed September 26, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2027-09-22 | Direct | 62,500 |
Reported balance
After 2017-09-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-09-22 · Grant · Acquired 62,500 · Balance 62,500 |
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2027-09-22 | Direct | 62,500 |
Reported balance
After 2017-09-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-09-22 · Grant · Acquired 62,500 · Balance 62,500 F1: The option becomes exercisable, if at all, on March 31, 2019, in three equal one-third increments if the average daily closing price of Altimmune, Inc.'s common stock on Nasdaq for 10 consecutive trading days between September 22, 2017 and December 31, 2018 is at or above one of three specified thresholds, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable, if at all, on March 31, 2019, in three equal one-third increments if the average daily closing price of Altimmune, Inc.'s common stock on Nasdaq for 10 consecutive trading days between September 22, 2017 and December 31, 2018 is at or above one of three specified thresholds, respectively.
DELCATH SYSTEMS, INC.
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 | Direct | 22,500 |
Reported balance
After 2026-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 22,500 · Balance 22,500 F1: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service.
SPECTRUM PHARMACEUTICALS INC
Report date June 18, 2020 · Filed June 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 40,000 |
Reported balance
After 2020-06-18 transaction · row 1
1 source rowRow 1 · 2020-06-18 · Grant · Acquired 30,000 · Balance 40,000 F1: 100% of the restricted shares shall vest on the earlier of (1) June 18, 2021 or (2) the date of the company's 2021 Annual Meeting of Stockholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2030-06-18 | Direct | 60,000 |
Reported balance
After 2020-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-18 · Grant · Acquired 60,000 · Balance 60,000 F2: One third of the aggregate amount of option shares shall vest on each of June 18, 2021, 2022 and 2023, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the restricted shares shall vest on the earlier of (1) June 18, 2021 or (2) the date of the company's 2021 Annual Meeting of Stockholders.
F2: One third of the aggregate amount of option shares shall vest on each of June 18, 2021, 2022 and 2023, respectively.
Scilex Holding Co
Report date January 17, 2023 · Filed January 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2033-01-17 | Direct | 350,000 |
Reported balance
After 2023-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-17 · Grant · Acquired 350,000 · Balance 350,000 F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.
Sorrento Therapeutics, Inc.
Report date May 18, 2022 · Filed May 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.51 · Expires 2032-05-18 | Direct | 350,000 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 350,000 · Balance 350,000 F1: 1/4th of the original number of shares subject to the option shall vest on May 18, 2023, and 1/48th of the original number of shares subject to the option shall vest on a monthly basis thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the original number of shares subject to the option shall vest on May 18, 2023, and 1/48th of the original number of shares subject to the option shall vest on a monthly basis thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Transcode Therapeutics, Inc.
Report date October 06, 2025 · Filed December 22, 2025
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 14, 2026 21:45 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001263500-26-000004 · form4-05142026_050505.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires not disclosed F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. F1 · derivative.expiration_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:10 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $16.05 | $0.00 |
DisclosureSEC source: 0001415889-25-013614 · form4-05192025_040507.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires not disclosed F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 15, 2025 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. F1 · derivative.expiration_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 15, 2025 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:32 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0001415889-24-014678 · form4-05282024_080529.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires not disclosed F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 23, 2024 and monthly thereafter for so long as the reporting person remains a director of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. F1 · derivative.expiration_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 23, 2024 and monthly thereafter for so long as the reporting person remains a director of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. Read SEC document |
| June 12, 2023 Filed Jun 22, 2023 01:18 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 19,682 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000899243-23-016196 · doc4.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,682 Underlying: Common Stock · 19,682 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on July 12, 2023 and monthly thereafter for so long as the reporting person remains a director of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 22:25 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0000899243-23-001870 · doc4.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2033-01-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 17:14 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001209191-22-031081 · doc4.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-05-18 F1 · derivative.exercise_date: 1/4th of the original number of shares subject to the option shall vest on May 18, 2023, and 1/48th of the original number of shares subject to the option shall vest on a monthly basis thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| May 04, 2022 Filed May 6, 2022 17:45 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Options · Derivative | 9,000 | $0.00 Strike: $6.24 | $0.00 |
DisclosureSEC source: 0000899243-22-017041 · doc4.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2023-05-04 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month on the first day of each month, with the first such vesting to occur on June 1, 2022 and monthly thereafter for so long as the reporting person remains a director of Delcath Systems, Inc. The option is subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 17:11 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0001209191-21-065539 · doc4.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-11-18 F1 · derivative.exercise_date: 1/12th of the original number of shares subject to the option shall vest on December 18, 2021, and 1/12th of the original number of shares subject to the option shall vest on a monthly basis thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:36 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000899243-21-032163 · doc4.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-08-05 F1 · derivative.exercise_date: The option immediately vested with respect to four-twelfths (4/12ths) of the option shares and the remaining option shares will vest and become exercisable at the rate of one-twelfth (1/12th) per month on the first day of each month for the next eight months, starting on September 1, 2021, for so long as the reporting person remains a director of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan). Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 23:02 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $11.67 | $0.00 |
DisclosureSEC source: 0000899243-20-032201 · doc4.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-10-01 F1 · date: The stock option was awarded on October 1, 2020 pursuant to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan (the "Plan"), subject to shareholder approval of the Plan. The Plan was approved by the stockholders of Delcath Systems, Inc. (the "Company") on November 23, 2020. F2 · derivative.exercise_date: The option vests ratably over the 36-month period beginning on October 1, 2020, provided that the reporting person remains a director of the Company as of each such vesting date. The option is exercisable immediately upon vesting. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 17:02 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-20-037982 · doc4.xml · derivative · entry 2 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-06-18 F2 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of June 18, 2021, 2022 and 2023, respectively. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 17:02 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037982 · doc4.xml · nonDerivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · shares: 100% of the restricted shares shall vest on the earlier of (1) June 18, 2021 or (2) the date of the company's 2021 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2019 Filed Jul 2, 2019 17:12 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001209191-19-040441 · doc4.xml · derivative · entry 2 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-20 F2 · derivative.exercise_date: 25% of the option shares vested on June 20, 2019. The remaining option shares shall vest in 25% equal annual amounts on each anniversary date of the grant over three years. Read SEC document |
| June 20, 2019 Filed Jul 2, 2019 17:12 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040441 · doc4.xml · nonDerivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: 100% of the restricted shares shall vest on the earlier of (1) June 20, 2020 or (2) the date of the company's 2020 Annual Meeting of Stockholders. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 22:36 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 62,500 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001012975-17-000719 · edgar.xml · derivative · entry 2 CZEREPAK ELIZABETH · CIK 0001263500 · CFO and EVP Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock, par value $0.0001 · 62,500 shares Expires 2027-09-22 F1 · derivative.exercise_date: The option becomes exercisable, if at all, on March 31, 2019, in three equal one-third increments if the average daily closing price of Altimmune, Inc.'s common stock on Nasdaq for 10 consecutive trading days between September 22, 2017 and December 31, 2018 is at or above one of three specified thresholds, respectively. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 22:36 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 62,500 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001012975-17-000719 · edgar.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · CFO and EVP Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock, par value $0.0001 · 62,500 shares Expires 2027-09-22 Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:32 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 18,727 | Not disclosed Strike: $13.38 | Not disclosed |
DisclosureSEC source: 0000899243-17-012356 · doc4.xml · derivative · entry 2 CZEREPAK ELIZABETH · CIK 0001263500 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,727 Underlying: Common Stock, par value $0.0001 · 18,727 shares Expires 2016-04-07 F2 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. F3 · derivative.exercise_date: The option is currently exercisable to purchase 6,250 shares of the Issuer's Common Stock. An additional 25% of the option will vest on each of 3/2/2018, 3/2/2019, and 3/2/2020. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:32 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 178,595 | Not disclosed Strike: $13.35 | Not disclosed |
DisclosureSEC source: 0000899243-17-012356 · doc4.xml · derivative · entry 1 CZEREPAK ELIZABETH · CIK 0001263500 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,595 Underlying: Common Stock, par value $0.0001 · 178,595 shares Expires 2025-05-27 F2 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. F1 · derivative.exercise_date: The option is currently exercisable to purchase 119,207 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"). The option to purchase the remaining 59,388 shares of Common Stock will vest in equal installments on a monthly basis until 4/7/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.